Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ME3241 in Healthy Adult Participants
NCT07422207Phase 1Recruiting
- Sponsor
- Meiji Pharma USA
- Start
- Mar 2026
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ME3241 with Placebo (2 arms). Primary endpoints: Incidence and severity of Adverse Events and Serious Adverse Events at 12 weeks, Changes in vital signs at 12 weeks and 8 more. Started Mar 2026; status: recruiting.
02
Drugs
ME3241
Beyond the preview
Go deeper on NCT07422207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422207.